Table 4 Symptoms based on interview by study nurse in patients by somatostatin analogue treatment for metastatic disease from small intestinal neuroendocrine tumour
| Â | Baseline | 1-year follow-up | ||
|---|---|---|---|---|
Lanreotide (N = 34) | Octreotide LAR (N = 54) | Total N = 88 | Total N = 77 | |
Acute complaints from the injections,n(%) | ||||
None | 17 (50.0%) | 24 (44.4%) | 41 (46.6%) | 44 (57.1%) |
Sore lumps beneath the skin | 11 (32.4%) | 14 (25.9%) | 25 (28.4%) | 22 (28.6%) |
Pain | 2 (5.9%) | 5 (9.3%) | 7 (8.0%) | 8 (10.4%) |
Other | 5 (14.7%) | 16 (29.6%) | 21 (23.8%) | 9 (11.7%) |
Persistent complaints from the injections,n(%) | ||||
None | 20 (58.8%) | 34 (63.0%) | 54 (61.4%) | 53 (68.8%) |
Sore lumps beneath the skin | 6 (17.6%) | 7 (13.0%) | 13 (14.8%) | 15 (19.5%) |
Pain | 1 (2.9%) | 3 (5.6%) | 4 (4.5%) | 2 (2.6%) |
Flatulence | 4 (11.8%) | 6 (11.1%) | 10 (11.4%) | 3 (3.9%) |
Diarrhoea | 5 (14.7%) | 5 (9.3%) | 10 (11.4%) | 2 (2.6%) |
Other | 6 (17.6%) | 7 (13.0%) | 13 (14.8%) | 6 (7.8%) |
Symptoms (based on interview) | ||||
Flatulence | 26 (76.5%) | 37 (68.5%) | 63 (71.6%) | 54 (71.1%) |
   ≥ 5 / day (% of total) | 10 (29.4%) | 10 (18.9%) | 20 (23.0%) | 14 (18.4%) |
2–4 / day (% of total) | 9 (26.5%) | 12 (22.6%) | 21 (24.1%) | 26 (34.2%) |
1–2 / day (% of total) | 7 (20.6%) | 14 (26.4%) | 21 (24.1%) | 14 (18.4%) |
Diarrhoea | 24 (70.6%) | 33 (61.1%) | 57 (64.8%) | 49 (64.5%) |
   ≥ 5 / day (% of total) | 6 (17.6%) | 14 (25.9%) | 20 (22.7%) | 14 (18.7%) |
2–4 / day (% of total) | 14 (41.2%) | 10 (18.5%) | 24 (27.3%) | 22 (29.3%) |
1–2 / day (% of total) | 4 (11.8%) | 9 (16.7%) | 13 (14.8%) | 12 (16.0%) |
Fatigue | 19 (55.9%) | 33 (61.1%) | 52 (59.1%) | 49 (63.6%) |
Abdominal discomfort | 21 (61.8%) | 28 (51.9%) | 49 (55.7%) | 37 (48.1%) |
Flushing | 12 (35.3%) | 20 (37.0%) | 32 (36.3%) | 32 (41.6%) |
   ≥ 5 / day (% of total) | 1 (2.9%) | 3 (5.6%) | 4 (4.5%) | 2 (2.6%) |
2–4 / day (% of total) | 0 | 5 (9.3%) | 5 (5.7%) | 6 (7.9%) |
1–2 / day (% of total) | 11 (32.4%) | 12 (22.2%) | 23 (26.1%) | 23 (30.3%) |
Depression/anxiety | 7 (20.6%) | 18 (33.3%) | 25 (28.4%) | 26 (33.8%) |
Partial hair loss | 10 (29.4%) | 15 (27.8%) | 25 (28.4%) | 22 (28.6%) |
Nausea | 7 (20.6%) | 12 (22.2%) | 19 (21.6%) | 12 (15.6%) |
Effects of diet | ||||
Reaction to certain food items | 22 (64.7%) | 33 (61.1%) | 55 (62.5%) | 47 (61.0%) |
Diarrhoea | 15 (44.1%) | 24 (44.4%) | 39 (44.3%) | 34 (44.2%) |
Flatulence | 16 (47.1%) | 22 (40.7%) | 38 (43.2%) | 30 (39.0%) |
Flushing | 2 (5.9%) | 2 (3.7%) | 4 (4.5%) | 4 (5.2%) |
Other | 6 (17.6%) | 9 (16.7%) | 15 (17.0%) | 12 (15.6%) |
Needs to avoid certain food | 13 (38.2%) | 22 (40.7%) | 35 (39.8%) | 29 (37.7%) |
Reacts to alcohol | 11 (32.4%) | 19 (35.8%) | 30 (34.5%) | 24 (32.0%) |